Dendritic cell-based treatment of cancer: closing in on a cellular therapy.
FH Valone, E Small, M MacKenzie, P Burch… - Cancer journal …, 2001 - europepmc.org
FH Valone, E Small, M MacKenzie, P Burch, M Lacy, MV Peshwa, R Laus
Cancer journal (Sudbury, Mass.), 2001•europepmc.orgPurpose Dendritic cells are the most potent antigen-presenting cells and are critical to
initiation of immune responses. Dendritic cells loaded ex vivo with tumor-associated antigen
are being administered to cancer patients in an effort to jump-start a potent, cell-mediated
anticancer immune response resulting in tumor shrinkage and clinical benefit.
initiation of immune responses. Dendritic cells loaded ex vivo with tumor-associated antigen
are being administered to cancer patients in an effort to jump-start a potent, cell-mediated
anticancer immune response resulting in tumor shrinkage and clinical benefit.
Purpose
Dendritic cells are the most potent antigen-presenting cells and are critical to initiation of immune responses. Dendritic cells loaded ex vivo with tumor-associated antigen are being administered to cancer patients in an effort to jump-start a potent, cell-mediated anticancer immune response resulting in tumor shrinkage and clinical benefit.
europepmc.org